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A newcomer in a cytokine family 
whose members regulate organ-
ism development, the regulatory 
cytokine transforming growth 
factor β (TGFβ) made its debut 
with the rise of the vertebrates. 
TGFβ evolved to regulate the 
expanding systems of epithelial 
and neural tissues, the immune 
system, and wound repair. Tied 
to these crucial regulatory roles 
of TGFβ are the serious conse-
quences that result when this 
signaling pathway malfunctions, 
namely tumorigenesis. Virtually 
all human cell types are respon-
sive to TGFβ. TGFβ maintains tis-
sue homeostasis and prevents 
incipient tumors from progress-
ing down the path to malignancy 
by regulating not only cellular 
proliferation, differentiation, sur-
vival, and adhesion but also the 
cellular microenvironment. But 
as genetically unstable entities, 
cancer cells have the capacity 
to avoid or, worse yet, adulter-
ate the suppressive influence of 
the TGFβ pathway. Pathological 
forms of TGFβ signaling promote 
tumor growth and invasion, eva-
sion of immune surveillance, and 
cancer cell dissemination and metastasis (Figure 1). How can a 
tumor-suppressor pathway be so radically turned on its head? 
The answer lies in the points of disruption in TGFβ signaling 
and the context in which these disruptions occur.
Malignant cells can circumvent 
the suppressive effects of TGFβ 
either through inactivation of core 
components of the pathway, such 
as TGFβ receptors (Figure 2, Path 
1), or by downstream alterations 
that disable just the tumor-sup-
pressive arm of this pathway (Fig-
ure 2, Path 2). If the latter mode 
of circumvention is used, cancer 
cells can then freely usurp the 
remaining TGFβ regulatory func-
tions to their advantage, acquiring 
invasion capabilities, producing 
autocrine mitogens, or releasing 
prometastatic cytokines. Thus, 
beheading of the TGFβ pathway 
by receptor inactivation can elimi-
nate tumor suppression, whereas 
amputation of just the growth-
inhibitory arm of this pathway 
not only abolishes growth sup-
pression but also creates added 
potential for tumor progression. 
Also relevant to cancer develop-
ment are the effects of TGFβ on 
the tumor stroma. TGFβ is a key 
enforcer of immune tolerance, and 
tumors that produce high levels of 
this cytokine may be shielded from 
immune surveillance. On the other 
hand, defective TGFβ responsive-
ness in immune cells can lead to 
chronic inflammation and the production of a protumorigenic 
environment. Tumor-derived TGFβ may recruit other stromal cell 
types such as myofibroblasts (at the invading tumor front) and 
osteoclasts (in bone metastases), thus furthering tumor spread.
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The transforming growth factor β (TGFβ) signaling pathway is a key player in metazoan biology, 
and its misregulation can result in tumor development. The regulatory cytokine TGFβ exerts 
tumor-suppressive effects that cancer cells must elude for malignant evolution. Yet, paradoxi-
cally, TGFβ also modulates processes such as cell invasion, immune regulation, and microenvi-
ronment modification that cancer cells may exploit to their advantage. Consequently, the output 
of a TGFβ response is highly contextual throughout development, across different tissues, and 
also in cancer. The mechanistic basis and clinical relevance of TGFβ’s role in cancer is becoming 
increasingly clear, paving the way for a better understanding of the complexity and therapeutic 
potential of this pathway.
Figure 1. The Role of TGFβ in Cancer
In normal and premalignant cells, TGFβ enforces homeostasis and 
suppresses tumor progression directly through cell-autonomous 
tumor-suppressive effects (cytostasis, differentiation, apoptosis) or 
indirectly through effects on the stroma (suppression of inflammation 
and stroma-derived mitogens). However, when cancer cells lose TGFβ 
tumor-suppressive responses, they can use TGFβ to their advantage 
to initiate immune evasion, growth factor production, differentiation 
into an invasive phenotype, and metastatic dissemination or to estab-
lish and expand metastatic colonies.Cell 134, July 25, 2008 ©2008 Elsevier Inc. 215
A dual role of TGFβ in cancer has long been noted, but 
its mechanistic basis, operating logic, and clinical relevance 
have remained elusive. What causes TGFβ signaling to be 
altered in cancer? What steps in tumor progression may 
benefit from a faulty TGFβ pathway? When does TGFβ act 
as a metastatic signal? And, most importantly, how can any 
of this knowledge be used to treat cancer? A combination 
of improved model systems, new tools for mechanistic dis-
section, and diligent mining of clinical data is providing fresh 
answers. Focusing on this progress, this review pays par-
ticular attention to new insights that are relevant to cancer 
in humans.
Operating Logic of the TGFβ System
The human TGFβ family comprises more than 30 factors that 
can be divided into two distinct branches. Factors such as 
activin, nodal, lefty, myostatin, and TGFβ are clustered in one 
family branch, and bone morphogenetic proteins (BMPs), 
anti-muellerian hormone (AMH, also known as MIS), and vari-
ous growth and differentiation factors (GDFs) are grouped into 
the other branch (Derynck and Akhurst, 2007; Roberts and 
Wakefield, 2003; Shi and Massagué, 2003). Activins, nodals, 
BMPs, AMH/MIS, and GDFs are key regulators of embryonic 
stem cell differentiation, body axis formation, left-right sym-
metry, and organogenesis. Roles of these cytokines in the 
adult organism, besides those mentioned for TGFβ, include 
regulation of gonadal function by activins and GDF9, inhibi-
tion of muscle development by myostatin, and bone growth 
and repair by BMPs. TGFβ family members display diverse 
spatial and temporal expression patterns. TGFβ1, for exam-
ple, is expressed in many cell types, whereas myostatin is 
expressed in just a few. The spectrum of temporal diversity in 
TGFβ expression is exemplified by AMH (brief developmental 
expression) and BMP2 (sustained expression throughout the 
organism’s lifetime).
Basics of the TGFβ System
Most members of this cytokine family 
exist in variant forms (e.g., TGFβ1, β2, 
and β3). The bioactive cytokine molecule 
is a dimer composed of a polypeptide 
chain that is cleaved from a precursor by 
enzymes such as furins and other con-
vertases. The active TGFβ dimer signals 
by bringing together two pairs of recep-
tor serine/threonine kinases known as 
the type I and type II receptors, respectively (Figure 3A). On 
binding TGFβ, the type II receptors phosphorylate and activate 
the type I receptors that then propagate the signal by phos-
phorylating Smad transcription factors. Receptors of the TGFβ 
branch of the cytokine family phosphorylate Smads 2 and 3, 
whereas those of the other branch such as BMP receptors 
phosphorylate Smads 1, 5, and 8 (Figure 3B). Once activated, 
the receptor substrate Smads (RSmads) shuttle to the nucleus 
and form a complex with Smad4, a binding partner common to 
all RSmads (Shi and Massagué, 2003).
Smad proteins possess DNA-binding activity, but the 
Smad4-RSmad complexes must associate with additional 
DNA-binding cofactors in order to achieve binding with 
high affinity and selectivity to specific target genes (Figure 
3A). These Smad partners are drawn from various families 
of transcription factors, such as the forkhead, homeobox, 
zinc-finger, bHLH, and AP1 families (Feng and Derynck, 
2005; Massagué et al., 2005). Each Smad4-RSmad-cofactor 
combination targets a particular set of genes, which is deter-
mined by the presence of cognate binding sequence element 
combinations in the regulatory regions of target genes. Acti-
vated Smad complexes additionally recruit transcriptional 
coactivators, corepressors, and chromatin remodeling fac-
tors. Through this combinatorial interaction with different 
transcription factors, a common TGFβ stimulus can activate 
or repress hundreds of target genes at once.
Contextual Pleiotropy and Signal Coordination
Built into this mode of TGFβ action are three cardinal features 
of TGFβ signaling, namely, pleiotropy, coordination, and con-
text dependence. The pleiotropic action of this pathway is 
based on the large set of transcription factors that can interact 
with activated Smads to target a large number of functionally 
diverse genes (Figure 3C). A series of surface hydrophobic 
patches and pockets on the Smad protein make it particu-
larly suitable for such interactions (Shi and Massagué, 2003). 
Figure 2. TGFβ and Tumor Progression
TGFβ induces tumor-suppressive effects that 
cancer cells must circumvent in order to develop 
into malignancies. Cancer cells can take two 
alternative paths to this end: (1) decapitate the 
pathway with receptor-inactivating mutations or 
(2) selectively amputate the tumor-suppressive 
arm of the pathway. The latter path allows cancer 
cells to extract additional benefits by co-opting 
the TGFβ response for protumorigenic purposes. 
In both cases, cancer cells can use TGFβ to 
modulate the microenvironment to avert immune 
surveillance or to induce the production of protu-
morigenic cytokines.216 Cell 134, July 25, 2008 ©2008 Elsevier Inc.
Figure 3. Organization of TGFβ Signaling and Weak Links in Cancer
(A) Ligand traps and coreceptor molecules control the access of TGFβ family ligands to signaling receptors. The ligand assembles a tetrameric complex of re-
ceptor serine/threonine kinases types I and II. Receptor-II phosphorylates and activates receptor-I, which then phosphorylates and activates Smad transcription 
factors (RSmads). Activated RSmads bind Smad4 and further build transcriptional activation and repression complexes to control the expression of hundreds 
of target genes in a given cell. Mitogen-activated protein kinases (MAPK) and other protein kinases phosphorylate Smads for recognition by ubiquitin ligases 
and other mechanisms of inactivation. Phosphatases have been identified that reverse these phosphorylation events.
(B) An abridged chart of ligand-receptor-coreceptor-Smad relationships in the TGFβ (green) and BMP (blue) branches of the TGFβ family. 
(C) Distinct combinations of transcription partner cofactors in different contexts (e.g., different cell types or conditions) determine the set of genes targeted by 
specific activated Smads. Each Smad-cofactor combination coordinately regulates a synexpression group of target genes. Smad signaling serves as a node 
for integrating regulatory signals that impinge on partner cofactors (e.g., Activator signal in Context 2).
(D) Alternative modes of TGFβ signaling include Smad4-independent RSmad signaling (via interactions with TIF1γ, IKKα, p68DROSHA), Smad-independent 
receptor-I signaling (via small G proteins and MAPK pathways), and direct receptor-II signaling (via Par6, and via LIMK1 in the case of BMPR-II).
(E) Core TGFβ pathway components that are affected by mutation (red), overexpression (black), or downregulation (green) in human cancers.Coordinated regulation of different genes is achieved by their 
sharing of enhancer element configurations that are recog-
nized by a particular Smad-cofactor complex. Within a TGFβ 
transcriptional program, this feature defines “synexpression 
groups” of coordinately regulated genes (Gomis et al., 2006a; 
Niehrs and Pollet, 1999; Silvestri et al., 2008). Cells of differ-
ent types or exposed to different conditions express different 
repertoires of Smad transcriptional partners, thus linking their 
TGFβ response to their cellular context. This operating logic 
allows for the remarkable plasticity of the TGFβ pathway and 
sets the stage for the severe consequences of its misguided 
activity in cancer.
Noncanonical TGFβ Signaling Pathways
Variant signaling branches and Smad-independent pathways 
coexist with the canonical Smad pathway in the response 
to TGFβ (Figure 3D). Smad4 is essential for many but not all 
TGFβ-regulated transcriptional responses. Indeed, ablation 
of SMAD4 in the mammary gland, liver, or pancreas of mice 
does not derail the development of the targeted organ even 
though the disruption of TGFβ family receptors does (Bardeesy 
et al., 2006; Li et al., 2003; Wang et al., 2005a). The existence 
of RSmad-dependent but Smad4-independent signaling func-
tions is supported by the identification of TIF1γ (transcription 
intermediate factor 1γ, also known as TRIM33) as a TGFβ sig-
nal mediator. TIF1γ interacts with receptor-activated Smad2/3 
in competition with Smad4 and participates in TGFβ-induced erythroid differentiation through as yet unknown targets (He et 
al., 2006). TIF1γ can also act as a Smad4 inhibitor (Dupont et 
al., 2005). Similarly, TGFβ-activated Smad2/3 in mouse kerati-
nocytes binds to IκB kinase α (IKKα) to control expression of 
the Myc oncogene antagonist MAD1 and keratinocyte differen-
tiation (Descargues et al., 2008). In a remarkable new finding, 
BMP-activated Smad1 and TGFβ-activated Smad2/3 bind to 
p68, a component of the microRNA (miRNA) processing com-
plex DROSHA, to target the primary miR-21 transcript (pri-
miR-21) for miR-21 production in vascular smooth muscle cells 
(Davis et al., 2008). The miRNA miR-21 induces a contractile 
cell phenotype by downregulating the suppressor PDCD4.
Smad-independent modes of TGFβ signaling also include the 
interaction of the TGFβ receptor complex with the interleukin-1 
receptor-effector module called IL1R-TRAF6-TAK1, leading to 
the activation of JNK and p38 mitogen-activated protein kinase 
(MAPK) signaling cascades (Lu et al., 2007). Through as yet 
unknown intermediates, the TGFβ receptor can also engage the 
Rho-Rock1 signaling module (Bhowmick et al., 2001), as well 
as the Cdc42/Rac1-PAK2 complex (Suzuki et al., 2007). The 
type II receptors can signal through substrates other than the 
type I receptors. In epithelial cells, TβR-II phosphorylates Par6, 
freeing it from a preformed Par6-TβR-I complex. This allows 
Par6 to trigger the dissolution of tight junctions in the context 
of epithelial-mesenchymal transitions (Ozdamar et al., 2005). 
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receptor substrates: Its unique C-terminal domain modulates 
the actin cytoskeleton regulatory kinase LIMK1 (Foletta et al., 
2003). Many of these noncanonical TGFβ signaling pathways 
have been investigated in cultured cells, but their relevance to 
human cancer remains to be established.
Points of Disruption in the TGFβ Pathway in Cancer
Under pressure to avoid tumor-suppressive effects, some can-
cer cells accumulate inactivating mutations in the TGFβ recep-
tors and the Smad proteins (Figure 3E), a pathway for which 
detailed accounts of the components have been made (Feng 
and Derynck, 2005; Massagué et al., 2005; Shi and Massagué, 
2003; Taylor and Wrana, 2008). A growing body of evidence 
also implicates the BMP pathway as a target of disruption in 
cancer. What follows is an abridged overview highlighting the 
points of disruptions in these pathways in cancer.
Signaling Receptors
Seven type I receptors and five type II receptors paired in dif-
ferent combinations provide the receptor system for the entire 
TGFβ family (Figure 3B). The cytoplasmic region of these 
receptors contains a serine/threonine kinase domain. A short 
segment (the GS domain) just N-terminal to the kinase domain 
in the type I receptors provides a switch for kinase activation. 
In the basal state, the GS domain presses against the active 
center of the kinase, repressing catalytic competence. Ligand-
dependent phosphorylation by a type II receptor switches the 
GS domain from a repressor element into a docking site for 
substrate Smad proteins. Most members of the TGFβ fam-
ily share several type I and type II receptors, but TGFβ is an 
exception. Among the type II receptors, only TβRII can bind 
to TGFβ. Furthermore, only TβRI can be incorporated into this 
TβRII-TGFβ complex (Groppe et al., 2008; Shi and Massagué, 
2003).
What alterations are found at the level of the TGFβ receptors in 
cancer? Biallelic inactivation of TGFBRII by mutations that trun-
cate the receptor protein or inactivate its kinase domain occur in 
colon, gastric, biliary, pulmonary, ovarian, esophageal, and head 
and neck carcinomas (for a detailed listing of known mutations, 
see Levy and Hill, 2006). TGFBRII mutations are highly repre-
sented in tumors with microsatellite instability, a pathological 
condition caused by mutations in replication mismatch repair 
genes. The TGFBRII coding region contains a 10-base poly-
adenine repeat prone to replication errors that insert or delete 
one or more adenines. These poly(A) errors remain unrepaired 
in tumors with microsatellite instability, yielding mutant TGFBRII 
alleles that encode inactive receptors. This mode of TGFBRII 
mutation is frequently seen in the inactivation of the second 
TGFBRII allele. Poly(A) tract TGFBRII mutations accumulate in a 
majority of sporadic gastrointestinal and biliary carcinomas with 
microsatellite instability, as well as in lung adenocarcinomas and 
gliomas. These mutations are also almost universally present 
in colon cancer patients with inherited mutations in mismatch 
repair genes. Interestingly, breast tumors and endometrial 
tumors with microsatellite instability do not accumulate TGF-
BRII mutations. Biallelic mutations in a poly(A) tract of the activin 
type II receptor ACVR2 occur in colon tumors with microsatellite 
instability alongside TGFBRII mutations, suggesting that ACVR2 
also plays a role in tumor suppression (Levy and Hill, 2006).218 Cell 134, July 25, 2008 ©2008 Elsevier Inc.Other mutation types such as frameshift and missense 
mutations in the TGFBRI coding region are present in sub-
sets of ovarian, esophageal, and head and neck cancers. A 
common hypomorphic allele, TGFBRI*6A, is associated with 
increased risk in certain types of cancers (Kaklamani et al., 
2004). Receptor alterations can also occur at the epigenetic 
level. Decreased expression of TGFBRI or TGFBRII occurs fre-
quently in lung, gastric, prostate, and bladder cancers. In gas-
tric cancer, this defect is linked to methylation of the TGFBRI 
promoter. Finally, germline mutations in the BMP type I recep-
tor BMPRIA occur in a subset of Juvenile Polyposis Syndrome 
(JPS) cases, an autosomal dominant disorder with predisposi-
tion to gastrointestinal polyps and cancer (Levy and Hill, 2006, 
and references therein).
Coreceptors and Ligand Traps
Various membrane proteins enhance binding of ligands to the 
receptors (Figure 3A) (Shi and Massagué, 2003). The mem-
brane-anchored proteoglycan betaglycan (also called TGFβ 
type III receptor) binds and presents TGFβ to the TGFβ type 
II receptor. Betaglycan also mediates the binding of the activin 
antagonist, inhibin, to activin receptors. The betaglycan-
related protein, endoglin (ENG), functions as a BMP9 corecep-
tor. Inherited mutations in Endoglin cause hemorrhagic telangi-
ectasia syndrome that also includes early-onset JPS (Sweet et 
al., 2005).
A structurally diverse group of proteins (ligand traps) that 
“trap” TGFβ family members to limit their access to mem-
brane receptors play critical roles during morphogenesis of the 
embryo and in the adult (De Robertis and Kuroda, 2004; Mas-
sagué and Chen, 2000). For example, the cleaved proregion of 
the TGFβ precursor called the latency-associated protein (LAP) 
sequesters TGFβ in a complex that is anchored to the extra-
cellular matrix by the latent TGFβ-binding proteins (LTBP1-4). 
A different set of proteins (noggin, chordin, gremlin, follista-
tin, DAN/cerberus, and Bmper) trap BMPs, whereas activins 
are trapped by follistatins and nodals by DAN/cereberus. Fol-
listatin overexpression is implicated in hepatocarcinogenesis 
(Rodgarkia-Dara et al., 2006) and breast cancer bone metas-
tasis (Kang et al., 2003b). Similarly, Gremlin-1 has been linked 
to skin basal cell carcinoma and other cancers (Sneddon et 
al., 2006).
Receptor Regulated Smad Proteins
RSmads act as a node for the integration of diverse signal-
ing pathways. In the basal state, RSmads undergo constant 
nucleocytoplasmic shuttling involving direct interactions with 
nuclear pore proteins as well as with importins and exportins 
(Xu, 2006). RSmad phosphorylation by type I receptors occurs 
at two C-terminal serine residues and triggers the accumu-
lation of RSmads in the nucleus. Cellular stress pathways 
and receptor tyrosine kinases activate MAPKs, which phos-
phorylate a linker region that joins the Smad N-terminal and 
C-terminal domains (MH1 and MH2 domains, respectively). 
Phosphorylation of these sites in Smad1 enables the binding 
of the E3 ubiquitin ligase Smurf1, which bars Smad1 interac-
tion with nucleoporins and leads to Smad1 polyubiquitination 
and degradation (Sapkota et al., 2007). Linker phosphorylation 
of Smad2/3 may similarly enhance the binding of other ubiq-
uitin ligases. The protein PPM1A may act as a Smad C-terminal 
phosphatase, whereas the proteins SCP1–3 function as linker 
and Smad1 C-terminal phosphatases (Lin et al., 2006; Sap-
kota et al., 2006). Thus, the opposing actions of TGFβ recep-
tor kinases and Smad phosphatases keep Smad proteins in a 
rapid activation-deactivation cycle, tying signal flow to recep-
tor activity.
Despite their crucial function in connecting signaling path-
ways, RSmad mutations are infrequent in cancer. Intragenic 
mutations in SMAD2 occur in a small proportion of colorectal 
cancers (Sjoblom et al., 2006), and loss of Smad3 expression 
has been noted in gastric cancer and T cell lymphoblastic leu-
kemia (Levy and Hill, 2006). SMAD2 is located on chromosome 
18q21, a region that suffers loss of heterozygosity in pancre-
atic and colon cancers. However, the minimal deleted region in 
18q21 also includes SMAD4/DPC4 (Deleted in Pancreatic Car-
cinoma locus 4), which is a well-established tumor suppressor 
(see below).
Co-Smads
In contrast to SMAD2 and SMAD3, SMAD4/DPC4 is a notable 
target of inactivation in cancer (reviewed in Levy and Hill, 2006). 
In pancreatic cancers, chromosome 18q21 deletions invariably 
affect SMAD4, and deletion or inactivating mutations disrupt 
the other allele. SMAD4 mutations, present in more than half 
of pancreatic carcinomas, are close in prevalence to mutations 
in KRAS, p53, and p16INK4A (Jaffee et al., 2002). SMAD4 is 
also mutated in more than half of sporadic colorectal tumors 
without microsatellite instability (but not in tumors with micro-
satellite instability), in a high proportion of esophageal tumors, 
and with less frequency in other cancers (Sjoblom et al., 2006). 
Germline SMAD4 mutations also occur in a subset of JPS 
cases. However, Smad4 inactivation in tumors is generally a 
late event linked to progression to overt carcinoma (see below). 
Interestingly, tumor-associated missense mutations in SMAD4 
cluster in the MH1 and MH2 domains of the protein and have 
thus proven to be highly informative in structural and functional 
studies of Smad4.
Smad Antagonists
Every step of the TGFβ pathway is tightly controlled by spe-
cialized factors, several of which also suffer alterations in 
human cancers. Smad6 and Smad7 are inhibitory Smads 
that negatively control TGFβ pathway activity in response to 
feedback loops and antagonistic signals (Massagué et al., 
2005). Smad6 competes with Smad4 for binding to receptor-
activated Smad1, and Smad7 recruits Smurf to TGFβ and 
BMP receptors for inactivation. Overexpression of Smad7 
and suppression of TGFβ signaling has been reported 
for endometrial carcinomas and thyroid follicular tumors 
(Cerutti et al., 2003; Dowdy et al., 2005). In immune cells of 
the colonic mucosa, Smad7 overexpression is associated 
with chronic inflammation, which predisposes the tissue to 
becoming cancerous (see below). Perhaps related to this 
defect, a genome-wide association study revealed that cer-
tain common alleles of SMAD7 are associated with colorec-
tal cancer (Broderick et al., 2007).
Smad function is also directly inhibited by transcriptional 
repressors such as Ski and SnoN (Ski-like). SKI and SKIL suffer 
deletions as well as amplifications in colorectal and esophageal 
cancers, raising the possibility that these genes act as onco-genes or tumor-suppressor genes depending on the context 
(Zhu et al., 2007). In acute myelogenous leukemia (AML), tran-
scriptional repressors encoded by the chimeric genes AML1/
EVI-1 from a 3:21 translocation and AML1/ETO from an 8:21 
translocation interact with Smad3 and suppress TGFβ signal-
ing (Letterio, 2005).
Sources of TGFβ in Tumors
In normal, unstressed tissue, sustained basal release of TGFβ 
by local sources may suffice for the maintenance of homeo-
stasis. However, under conditions of tissue injury, TGFβ is 
abundantly released by blood platelets and various stromal 
components to prevent runaway regenerative cell proliferation 
and inflammation. Such conditions occur in tumors as well. 
Indeed, TGFβ is frequently present in the tumor microenviron-
ment, initially as a signal to prevent premalignant progression, 
but eventually as a factor that malignant cells may use to their 
own advantage. The presence of TGFβ has been documented 
in many subsets of tumors (commonly assayed by Smad2 
C-terminal phosphorylation; Xie et al., 2002), indicating that 
this cytokine is prominently associated with cancer.
Sources of TGFβ in tumors vary and include the cancer cells 
themselves as well as various cells of the tumor stroma, with 
each source leading to context-dependent functional conse-
quences. Tumors are infiltrated by leukocytes, macrophages, 
and bone marrow-derived endothelial, mesenchymal, and 
myeloid precursor cells. The presence of these tumor-infil-
trating cells coincides with TGFβ secretion and is thus a sus-
pected source of the accumulation of TGFβ1 at the invasion 
front of the tumor (Yang et al., 2008). The presence of TGFβ1 
in this location is associated with tumor progression (Dalal et 
al., 1993). Specialized local sources of TGFβ are also impor-
tant in the context of metastasis. The bone matrix stores TGFβ, 
which becomes mobilized during osteolytic metastasis (Kings-
ley et al., 2007). Activation of latent TGFβ is a complex process 
involving diverse enzymatic and nonenzymatic activities that 
are likely to vary in different tumors.
Tumor Suppression by TGFβ
The frequent disruption of TGFβ and BMP receptors and of 
Smad4 in cancer reflects the relevance of the tumor suppres-
sive roles of these pathway components. However, these roles 
are highly contextual, both in terms of the tumor stage and 
suppressor mechanism that are targeted by these pathways.
Suppression of Premalignant Progression
Despite the occurrence of TGFβ receptor mutations in cancer, 
tissue-specific inactivation of TGFBRII alone in mouse models 
seldom leads to spontaneous tumor formation. Targeted dele-
tion of TGFBRII in the mouse mammary epithelium resulted 
in excessive lobular-alveolar cell proliferation (hyperplasia; 
Forrester et al., 2005). However, no developmental or patho-
logical changes were apparent upon deletion of TGFBRII in 
the epithelia of the oral cavity, esophagus, forestomach (Lu et 
al., 2006), pancreas (Ijichi et al., 2006), intestine (Muñoz et al., 
2006), or skin (Guasch et al., 2007) of mice. Also, no disrup-
tion of normal development or spontaneous tumor formation 
was apparent upon tissue-restricted SMAD4 ablation in the 
mouse liver (Wang et al., 2005b) or pancreas (Bardeesy et al., Cell 134, July 25, 2008 ©2008 Elsevier Inc. 219
Figure 4. Blocking Premalignant  
Progression by Tumor-Suppressor Proteins
(A) TGFβ and BMP suppress the progression 
of premalignant states in mouse models. Ge-
netic ablation of TGFβ or BMP receptor genes 
(TGFBRII and BMPR1A, respectively) or SMAD4 
alone does not normally lead to carcinoma for-
mation. However, inactivation of these pathways 
allows carcinoma progression in transitional epi-
thelia and in premalignant lesions caused by on-
cogene (KRAS) activation or tumor-suppressor 
gene (APC) inactivation.
(B) Influence of the context on choice of TGFβ 
tumor-suppressor response. Cells under nor-
mal conditions are generally wired for cytostatic 
or differentiation responses to TGFβ; a loss of 
TGFβ signaling in this context causes elevated 
but still regulated cell proliferation (hyperplasia). 
In contrast, premalignant cells and other hyper-
proliferative cell states are wired for apoptotic 
and senescence responses; a loss of TGFβ sig-
naling in this context enables tumor progression 
(neoplasia).2006), although Smad4 deficiency in mouse mammary glands 
did cause spontaneous squamous cell carcinomas involving 
transdifferentiation of mammary epithelium to squamous epi-
thelium (Li et al., 2003). Indeed, the role of TGFβ in constrain-
ing epithelial growth only becomes readily apparent under 
conditions of tissue injury or oncogenic stress. Skin wounds 
heal faster, with a rapid rate of keratinocyte proliferation and 
migration, in SMAD3 null mice (Ashcroft et al., 1999) and mice 
with targeted deletion of TGFBRII in basal keratinocytes of 
stratified epithelia (Guasch et al., 2007). Moreover, deficien-
cies in TGFBRII or SMAD4 strongly accelerate the malignant 
progression of neoplastic lesions initiated by oncogenic stim-
uli (Figure 4A). Ablation of TGFBRII favors carcinoma conver-
sion of intestinal polyps initiated by inactivation of the APC 
(Adenomatous Polyposis Coli) gene or chemical mutagenesis 
(Biswas et al., 2004; Muñoz et al., 2006). The same is observed 
for mammary tumors initiated by polyoma virus middle-T 
oncogene (PyMT) (Forrester et al., 2005) and premalignant 
lesions initiated by KRAS oncogene in the pancreas (Ijichi et 
al., 2006), the oral and esophageal epithelium (Lu et al., 2006), 
or the skin (Guasch et al., 2007). Heterozygous inactivation of 
SMAD4 does not cause carcinomas on its own but potentiates 
the progression of intestinal polyps to carcinoma in APC-defi-
cient mice with loss of the remaining wild-type SMAD4 allele 
(Takaku et al., 1998). Likewise, KRAS-induced premalignant 
pancreatic lesions progress to intraductal papillary mucinous 
neoplasia when combined with deletion of SMAD4 (Bardeesy 
et al., 2006). Intriguingly, a constitutively activated TGFBRI 
transgene has an inhibitory effect on mammary tumors driven 
by the oncogene ErbB2/HER2, possibly reflecting a stifling of 
malignant conversion by the TGFβ receptor (Muraoka et al., 
2003; Siegel et al., 2003). These findings are consistent with 
the fact that somatic mutation of SMAD4 in pancreatic cancer 
and of TGFBRII or SMAD4 in colorectal cancer emerge dur-
ing the adenoma to carcinoma transition (Jaffee et al., 2002; 
Jones et al., 2008).220 Cell 134, July 25, 2008 ©2008 Elsevier Inc.Contextual Choice of Tumor-Suppressor Effects
A detailed analysis of the effect of TGFBRII ablation in strati-
fied epithelia of mice has shed light on the circumstances that 
engage TGFβ as an enforcer of epithelial homeostasis and a 
suppressor of tumor progression (Guasch et al., 2007). Under 
wild-type conditions, the antiproliferative effects of TGFβ on 
epithelial cells counter the effects of local mitogenic stimula-
tion. In the absence of TGFBRII, TGFβ-independent apopto-
sis limits hyperplasia. However, under conditions of intense 
mitogenic stimulation, such as those that occur naturally in the 
transitional epithelia of the anogenital region or pathologically 
as a result of KRAS oncogene expression, the TGFβ pathway 
engages proapoptotic mechanisms to offset the elevated rate 
of cell proliferation. Thus, TGFβ triggers cytostasis or apop-
tosis depending on the intensity of the proliferative signals 
(Figure 4B). In the absence of TGFBRII, transitional epithelia 
and premalignant cells generate squamous cell carcinomas. 
Similarly, mice with a targeted disruption of BMPR1A develop 
polyps in the intestinal epithelium but carcinomas in the gas-
trointestinal transitional zone (Bleuming et al., 2007).
The dependence of TGFβ apoptotic responses on contex-
tual determinants is also apparent in the mammary epithelium. 
In mouse mammary glands, TGFβ expression occurs in virgin 
female mice and well into pregnancy without causing apoptosis. 
It subsides during late pregnancy and lactation. Weaning trig-
gers a sharp surge in TGFβ3 expression, which participates in 
the massive wave of apoptosis that drives involution (Nguyen 
and Pollard, 2000). Expression of a constitutively active TGFBRI 
transgene in the mammary epithelium causes apoptosis only 
during late pregnancy (Siegel et al., 2003). Interestingly, primary 
epithelial cell cultures from late-pregnancy glands respond to 
TGFβ with cytostasis, not with apoptosis. Apoptosis also occurs 
in hyperplastic lesions of TGFBRII null mammary epithelium (For-
rester et al., 2005). Thus, the competence to mount an apoptotic 
response to TGFβ is tied to conditions of intense proliferative 
activity and to as yet unknown environmental cues.
Cell-Autonomous Tumor-Suppressor Mechanisms
Insights into the mechanisms that mediate TGFβ-dependent 
cytostasis, differentiation, or apoptosis are provided by the 
molecular dissection of this pathway in model cell systems and 
the ongoing validation of these findings in mouse models and 
human tumor tissue samples.
Cytostatic Mechanisms
TGFβ inhibits progression of cell cycle phase G1 through two 
sets of events: mobilization of cyclin-dependent kinase (CDK) 
inhibitors and suppression of c-Myc (Figure 5A). In epithelial 
cells, TGFβ induces expression of p15Ink4b, which inhibits 
cyclinD-cdk4/6 complexes, and of p21Cip1, which inhibits 
cyclinE/A-cdk2 complexes. Smad3/4 complexes with FoxO 
transcription factors to target the p15INK4b and p21CIP1 
promoters for transcriptional activation (Gomis et al., 2006b; 
Figure 5. Tumor-Suppressive Transcriptional Responses to TGFβ
(A) A TGFβ-activated Smad complex in epithelial cells represses c-MYC ex-
pression (right panel) and facilitates the induction of CDK inhibitory genes (left 
panel). Smad-FoxO complexes target p15INK4b and p21CIP1 for transcrip-
tional induction, leading to CDK inhibition. The resulting surge of p15Ink4b 
releases p27Kip1 from a latent Cdk4-bound state to inhibit CDKs further. 
FoxO factors can be inhibited by the antagonistic family member FoxG1 or by 
Akt-mediated phosphorylation in tumors with a hyperactive PI3K-Akt path-
way. Overexpression of the C/EBPβ isoform LIP in metastatic breast cancer 
inhibits C/EBPβ, a common partner of c-MYC and p15INK5b regulatory Smad 
complexes.
(B) Different cell types engage different CDK inhibitor in their TGFβ cytostatic re-
sponse, whereas c-MYC downregulation is a general feature of the response.
(C) p16INK4a induction by endogenous sensors of hyperactive Ras (or other 
oncogenic signals) collaborates with p15INK4b to mediate tumor suppression.
(D) ID1 repression creates conditions for terminal differentiation and senes-
cence. Differential effects of BMP and TGFβ on ID1 expression are based on 
the ability of TGFβ-activated Smads to recruit the transcriptional repression 
factor ATF3 to the ID1 regulatory region. Expression of ATF3 itself is induced 
by the Smad pathway.Seoane et al., 2004). Induction of these genes also requires Sp1 
(Pardali et al., 2000). Another CDK inhibitor, p27Kip1, under-
goes mobilization from an inactive state bound to cyclin D-cdk4 
to an active state that is displaced from these complexes by 
p15Ink4b to target cyclin E/A-cdk2 (Figure 5B). TGFβ stimu-
lates expression of p21Cip1 in T cells (Wolfraim et al., 2004), 
of p57Kip2 in hematopoietic stem/progenitor cells (Scandura 
et al., 2004), and of p15Ink4b and p21Cip1 in astrocytes and 
neural progenitor cells (Rich et al., 1999; Seoane et al., 2004) 
(Figure 5B). Thus, the particular CDK inhibitors involved in a 
TGFβ cytostatic response depend on the cell type.
c-MYC is a key transcriptional inducer of cell growth and 
division. In keratinocytes and mammary epithelial cells, c-MYC 
downregulation is mediated by a TGFβ-induced protein com-
plex containing Smad3/4, p107, E2F4/5, and C/EBPβ (Chen 
et al., 2002; Gomis et al., 2006b). Smad3/4 and E2F4/5 rec-
ognize a proximal element in the c-MYC promoter and p107 
is thought to recruit corepressors. Interestingly, C/EBPβ is 
required for repression of c-MYC by this complex and for acti-
vation of p15INK4b by a Smad3/4-FoxO complex (Gomis et al., 
2006b). Thus, C/EBPβ coordinates the p15INK4b and c-MYC 
responses to TGFβ. Additional coordination is provided by the 
transcription factor Miz-1, which in proliferating cells recruits 
c-Myc as a repressor to the transcriptional start regions of the 
p15INK4b and p21CIP1 promoters (Seoane et al., 2002; Staller 
et al., 2001) (Figure 5A).
As cotransducers of Smad signals, FoxO, E2F4/5, and C/
EBPβ integrate multiple inputs into the TGFβ cytostatic pro-
gram. Signals that regulate C/EBPβ can influence the effects 
of TGFβ on c-MYC and p15INK4b expression, whereas signals 
that inhibit FoxO activity, such as Akt-mediated phosphoryla-
tion or FoxO interaction with the inhibitory factor FoxG1, inhibit 
p15INK4b and p21CIP1 induction (Seoane et al., 2004).
Cell Differentiation and Senescence
TGFβ and other members of its family have a major influ-
ence on cell lineage determination and terminal differentia-
tion. Whereas certain effects of TGFβ on differentiation can 
be co-opted for tumor progression (see below), others sup-
press tumorigenesis by driving precursor cells into a less pro-
liferative state. TGFβ promotes the differentiation of mesen-
chymal precursors into fibroblasts and myofibroblasts at the 
expense of adipocyte, myocyte, and osteoblast fates (Figure 
6) (Derynck and Akhurst, 2007). BMP promotes differentiation 
of mesenchymal precursors toward the osteoblast lineage 
and of neural precursors into astroglia. BMP signaling in skin 
and intestinal epithelia is required for stem cell maintenance 
but also for progenitor cell differentiation (He et al., 2004; 
Kobielak et al., 2007). BMPR1A ablation studies suggest that 
when stem cells transit into a progenitor state, BMP interferes 
with Wnt signaling to promote differentiation. Failure of this 
mechanism could be the basis for intestinal polyp formation 
in JPS patients with BMPR1A mutations.
TGFβ also modulates differentiation through the regulation of 
Id proteins (Inhibitor of Differentiation/DNA binding) that nega-
tively regulate cell differentiation by interfering with prodiffer-
entiation bHLH transcription factors (Ruzinova and Benezra, 
2003). In mouse embryonic stem cells, BMP-activated Smad-
Stat3 complexes induce ID1 expression to stimulate self-Cell 134, July 25, 2008 ©2008 Elsevier Inc. 221
Figure 6. Anti- and Protumorigenic Effects of TGFβ on Cell Differentiation
(A) TGFβ favors epithelial differentiation into less proliferative states partly through the downregulation of Inhibitor of Differentiation/DNA binding 1 (ID1). But be-
cause of as yet unknown determinants, epithelial progenitor cells can instead become competent to undergo epithelial-mesenchymal transition (EMT) in response 
to TGFβ. TGFβ functions through the transcription factors SNAIL and SLUG and through phosphorylation of the cell-cell contact regulator Par6 to stimulate EMT. 
TGFβ also stimulates the differentiation of mesenchymal progenitor cells toward fibroblast and myofibroblast lineages, at the expense of adipocyte and musculo-
skeletal lineages.
(B) Carcinoma cells may avert differentiation into a less proliferative state by switching the ID1 response to TGFβ from repression to activation, as observed in 
breast cancer cells. Carcinoma progenitor cells that are competent to undergo EMT in response to TGFβ yield highly motile, invasive mesenchymal derivatives, 
whose presence in tumors is associated with metastatic dissemination.renewal (Ying et al., 2003). In epithelial and endothelial cells in 
culture, BMP stimulates and TGFβ downregulates ID1 expres-
sion (Kang et al., 2003a; Korchynskyi and ten Dijke, 2002) (Fig-
ure 5D). BMP-induced binding of Smad1 to the ID1 promoter 
supports transcriptional activation, whereas TGFβ signaling 
through Smad3 induces the expression of the repressor ATF3, 
which is then recruited by Smad3 to the ID1 promoter (Kang 
et al., 2003a). ID1 enhances Ras-driven mammary tumorigen-
esis in mice by bypassing senescence (Swarbrick et al., 2008). 
In a xenograft model using a Ras-transformed human breast 
epithelial cell line, TGFβ suppressed tumor formation by these 
cells through downregulation of ID1, thereby imposing a less 
proliferative phenotype (Tang et al., 2007). These findings sug-
gest that ID1 downregulation mediates cell differentiation and 
senescence as tumor-suppressive responses to TGFβ.
Proapoptotic Mechanisms
In physiological settings, TGFβ triggers apoptosis depending 
on cell-autonomous and environmental factors whose molecu-
lar identity remains unknown. The nature of these determinants 
needs to be defined and replicated in model systems in order to 
properly delineate TGFβ proapoptotic mechanisms that suffer 
disruption in cancer. Although the mechanism of TGFβ-induced 
apoptosis in vivo remains to be established, candidates include 
several Smad-dependent and -independent mechanisms 
observed in cell lines (reviewed in Pardali and Moustakas, 2007). 
These mechanisms include the induction of the death-associ-
ated protein kinase DAPK, which triggered apoptosis in a hepa-
toma cell line, the signaling factor GADD45b, which triggered 
apoptosis in hepatocytes, and the death receptor FAS and the 
proapoptotic effector BIM, which triggered apoptosis in gastric 
carcinoma cell lines. Induction of the 5′ inositol phosphatase 
SHIP interfered with activation of the PI3K-Akt prosurvival path-222 Cell 134, July 25, 2008 ©2008 Elsevier Inc.way. Smad interaction with Akt and TGFβ receptor interactions 
with the p38 MAPK activator DAXX have also been proposed as 
mediators of proapoptotic effects.
Tumor Suppression through the Stroma
In addition to its direct growth-inhibitory effects on target cells, 
TGFβ can restrict epithelial cell proliferation and tumor formation 
by blocking the production of paracrine factors in stromal fibro-
blasts and inflammatory cells. These observations bring growing 
attention to the notable role of the stroma in tumor development.
Suppression of Fibroblast-Derived Mitogens
Epithelial interactions with adjacent stroma are important in guid-
ing tissue morphogenesis and homeostasis. A role for TGFβ in 
such interactions emerged from work in mice with defective TGFβ 
signaling in stromal fibroblasts. Expression of a dominant-neg-
ative TGFBRII transgene in the mammary stroma increased the 
lateral branching of adjacent mammary ducts. Building on this 
observation, Bhowmick et al. (2004) generated mice with a tar-
geted deletion of TGFBRII in fibroblasts. Such loss of TGFβ sig-
naling in the prostate and the forestomach resulted in hyperplasia 
of the adjacent epithelia with progression to prostatic intraepithe-
lial neoplasia and gastric squamous carcinoma, respectively (Fig-
ure 7A). These effects were accompanied by an elevated expres-
sion of hepatocyte growth factor (HGF) in the TGFBRII-defective 
fibroblasts and activation of the HGF receptor Met in adjacent 
epithelial cells. By constraining the expression of mitogenic fac-
tors in stromal fibroblasts, TGFβ limits the paracrine stimulation of 
epithelial proliferation and suppresses tumor development.
Suppression of Tumorigenic Inflammation
TGFβ is a key suppressor of destructive immune and inflam-
matory reactions, as first shown by the lethal multifocal inflam-
matory disease arising in TGFβ1-deficient mice and mice with 
a conditional deletion of TGFBRII in the hematopoietic system 
(reviewed in Li et al., 2006; Rubtsov and Rudensky, 2007). 
Smad3-deficient mice also have a phenotype of impaired 
immune regulation with excessive expansion of T cell popula-
tions, defective mucosal immunity, and chronic inflammation. 
As an immunosuppressive cytokine, TGFβ inhibits the devel-
opment, proliferation, and function of both the innate and the 
adaptive arms of the immune system. Targets of TGFβ include 
CD4+ effector T cells (Th1 and Th2), CD8+ cytotoxic T cells 
(CTLs), dendritic cells, NK cells, and macrophages (Figure 7B). 
Additionally, TGFβ stimulates the generation of regulatory T 
cells (Treg), which inhibit effector T cell functions, and IL17-pro-
ducing Th17 cells, which regulate NK cells and macrophages.
By curtailing the activities of macrophages, natural killer (NK) 
cells, and effector T cells, TGFβ suppresses inflammation to 
promote immune tolerance. Tolerance is particularly important 
in the intestinal mucosa, where reactions to commensal flora 
and to food antigens must be restrained (Becker et al., 2006). 
Breakdown of mucosal immune tolerance underlies the patho-
genesis of inflammatory bowel diseases (ulcerative colitis and 
Crohn’s disease) that are associated with an increased risk for 
colon cancer. Malfunctions in TGFβ signaling are suspected to 
be a root cause of these conditions. TGFβ1-defective mice and 
Smad3-deficient mice develop precancerous colon lesions 
with submucosal inflammation, which frequently progress to 
colon carcinoma (Engle et al., 2002; Maggio-Price et al., 2006). 
Inflammation and tumor formation in these animals required 
their removal from a germ-free environment or infection with 
the bacteria Helicobacter. Remarkably, T cells isolated from 
colon samples of patients with inflammatory bowel disease are 
poorly responsive to TGFβ because of the expression of high 
levels of Smad7 (Monteleone et al., 2004) (Figure 7C). Dense 
infiltrates of proinflammatory cells are also present in the 
nonpolypous intestinal mucosa of JPS patients with SMAD4 
germ line mutations. Notably, the selective ablation of SMAD4 
in the T cell compartment leads to a JPS-like phenotype in 
mice, which results in gastrointestinal tumors that are heavily 
infiltrated with plasma cells. In contrast, deletion of SMAD4 in 
the intestinal epithelium alone does not lead to spontaneous 
tumor formation (Kim et al., 2006; SMAD4+/− mice do develop 
intestinal tumors, but this requires a primed, APC-defective 
genetic background; Takaku et al., 1998). TGFβ can also sup-
press gastrointestinal inflammatory activity by stimulating the 
expression of the prostaglandin-degrading enzyme 15-PGDH, 
which antagonizes the proinflammatory action of COX2 (Yan 
et al., 2004).
Failure of Tumor-Suppressor Mechanisms
We have seen that mutational inactivation of core pathway 
components occurs in large subsets of colorectal, pancreatic, 
ovarian, gastric, and head and neck carcinomas. However, 
breast cancers, prostate cancers, gliomas, melanomas, and 
hematopoietic neoplasias are a different story. These cancers 
preferentially disable the tumor-suppressive action of TGFβ by 
losing the tumor-suppressive arm of the signaling pathway. A 
striking example of this preference is provided by breast can-
cers with microsatellite instability, which rarely progress when 
TGFBRII is lost. TGFβ receptor mutations surely occur in these 
tumors, but the resulting clones must be at a disadvantage 
compared to clones that lose the tumor-suppressive arm of 
the TGFβ pathway.
Defective Cytostatic Gene Responses
Tumor-derived cell lines contain a variety of alterations that 
disable cytostatic Smad cofactors. However, some of these 
alterations may be the result of adaptation to growth in vitro 
because they are also found in certain cell lines derived from 
normal tissue. To obviate this concern, recent studies have 
focused on short-term cultures of patient-derived cancer cell 
samples. Breast cancer cells from pleural fluids of patients 
with metastatic disease expressed normal TGFβ receptor 
and Smad functions but showed a partial or complete loss of 
cytostatic response to TGFβ in all cases (Gomis et al., 2006b). 
Figure 7. Anti- and Protumorigenic Effects 
of TGFβ in the Stroma
(A) TGFβ suppresses tumor emergence in certain 
epithelial tissues (e.g., the forestomach epithe-
lium) by inhibiting the production of cell survival 
and motility factors such as hepatocyte growth 
factor (HGF).
(B) TGFβ acts as a major enforcer of immune toler-
ance by inhibiting the development and functions 
of nearly all major components of the innate (red) 
and adaptive (black) immune system. Some of 
these effects are exerted through the activation of 
regulatory T cells (Treg; green) that constrain the 
function of other lymphocytes (gray).
(C) By imposing limits on the inflammatory re-
sponse, TGFβ can avert the protumorigenic ef-
fect that could derive from chronic inflammation, 
as observed in colonic epithelial cells. However, 
T cells in some patients with inflammatory bowel 
disease (a colon cancer-prone condition) overex-
press Smad7 and are not sensitive to TGFβ.
(D) In some types of cancer, a defective TGFβ re-
sponse in inflammatory cells can lead to excessive 
inflammation, favoring tumor progression. In other 
types of cancer, tumor-derived TGFβ can sup-
press antitumor immune responses, which also 
favors tumor progression.Cell 134, July 25, 2008 ©2008 Elsevier Inc. 223
Half of the samples in this study lacked p15INK4b induction 
and c-MYC repression despite retaining other TGFβ gene 
responses. This defect was associated with overexpression of 
the dominant-negative C/EBPβ isoform LIP, which binds and 
inhibits the transcriptional active isoform LAP (Figure 5A). Inde-
pendent studies have established an association between a 
high LIP:LAP ratio and tumor aggressiveness in breast cancer 
(Zahnow et al., 1997).
Patient-derived metastatic breast cancer cells were also 
uniformly aberrant in the ID1 response to TGFβ, which was 
induced instead of repressed (Padua et al., 2008). ID1 expres-
sion is part of a lung metastasis gene-expression signature 
that is associated with relapse in estrogen receptor negative 
(ER−) breast cancer patients (Minn et al., 2005). In xenograft 
assays in mice using human breast cancer cell lines, the pro-
teins Id1 and Id3 were essential for tumor reinitiation after the 
cells entered the lung parenchyma (Gupta et al., 2007). There-
fore, the ID1 response to TGFβ switches from tumor suppres-
sive to prometastatic in breast cancer.
Loss of Cytostatic Genes
A subset of gliomas sustain homozygous deletion of p15INK4b, 
eliminating this mediator of TGFβ tumor-suppression action 
(Jen et al., 1994). The p15INK44b locus on chromosome 9p21 
encodes two additional cell cycle inhibitors, p16INK4a and ARF, 
whose functional and clinical relevance as tumor suppressors 
is well established. A tumor-suppressor role for p15INK4b 
has been demonstrated in mouse models, in which ablation 
of p15INK4b increased the rate and diversity of tumors that 
develop in mice that are null for p16INK4a or for p16INK4a and 
ARF (Krimpenfort et al., 2007). Loss of p15INK4b in the mice 
specifically promoted the emergence of skin squamous cell 
and basal carcinomas, as well as intestinal carcinomas. Thus, 
deleterious mitogenic signals may trigger tumor-suppressor 
responses by activating p16INK4a through internal sensors 
and by activating p15INK4b through TGFβ (Figure 5C). A loss 
of p15INK4b would weaken TGFβ tumor-suppression activ-
ity, which, combined with a loss of p16INK4a, would lead to 
tumor progression. A loss of responsiveness to TGFβ may also 
be embedded in the pleiotropic consequences of oncogene 
activation. For example, oncogenic Ras signaling may inhibit 
Smads through linker phosphorylation, whereas the overex-
pression c-MYC or Cyclin D1 in certain cancers may blunt the 
effect of TGFβ-induced CDK inhibitors.
Tumorigenic Effects of TGFβ: Tumor Growth, Invasion, 
and Immune Evasion
Cancer cells that lose the tumor-suppressive arm of the TGFβ 
pathway accrue tumorigenic effects that directly enhance 
tumor growth and invasion. However, regardless of how they 
avert the tumor-suppressive action, cancer cells can benefit 
from tumor-derived TGFβ by using it as a shield against anti-
tumor immunity.
Epithelial-Mesenchymal Transition
Epithelial-mesenchymal transition (EMT) is a well-coordinated 
process during embryonic development and a pathological 
feature in neoplasia and fibrosis (Thiery, 2003). Cells undergo-
ing EMT lose expression of E-cadherin and other components 
of epithelial cell junctions. Instead, they produce a mesenchy-224 Cell 134, July 25, 2008 ©2008 Elsevier Inc.mal cell cytoskeleton and acquire motility and invasive proper-
ties. EMT is key in gastrulation and in the genesis of the neural 
crest, the somites, the heart, and craniofacial structures. It is 
driven by a set of transcription factors including the zinc-finger 
proteins Snail and Slug, the bHLH factor Twist, the zinc-finger/
homeodomain proteins ZEB-1 and -2, and the forkhead factor 
FoxC3.
The competence of epithelial precursor cells to undergo EMT 
becomes manifest in response to cues that prominently feature 
TGFβ (Figure 6A). As such, TGFβ-induced EMT is observed in 
transformed epithelial progenitor cells with tumor-propagating 
ability (Figure 6B) (Mani et al., 2008). EMT-like processes con-
tribute to tumor invasion and dissemination owing to the cell 
junction-free, motile phenotype that they confer. Carcinoma 
cells with mesenchymal traits have been observed in the inva-
sion front of carcinomas and may reflect a series of intercon-
nected features: that carcinomas are propagated by trans-
formed progenitor cells, that progenitor cells are competent 
to undergo EMT, that EMT is triggered by cues at the invasion 
front, and that EMT augments the disseminative capacity of 
these cells. That said, not all cells that undergo EMT are tumor-
propagating cells, and not all tumor-propagating cells are nec-
essarily competent to undergo EMT.
TGFβ is a potent inducer of EMT (first reported in mouse 
heart formation and palate fusion, in some mammary cell lines, 
and in mouse models of skin carcinogenesis; Derynck and 
Akhurst, 2007; Thiery, 2003). A role of TGFβ-induced EMT in 
human cancer is suggested by the gene expression analysis of 
tumor-propagating breast cancer cell populations expressing 
the cell surface markers CD44+/CD24lo (Shipitsin et al., 2007). 
The common gene expression pattern of these cells from differ-
ent cancer patients suggested the presence of an active TGFβ 
pathway. Furthermore, treatment with a TβR-I kinase blocker 
induced these cells to adopt a more epithelial phenotype. 
Thus, CD44+/CD24lo breast cancer cells may represent a tumor 
cell population that has undergone EMT. In human carcinomas, 
cells with features characteristic of EMT have been observed 
in the invasion front, a location that is rich in stromal TGFβ and 
other cytokines that may cooperate in EMT induction.
TGFβ promotes EMT by a combination of Smad-dependent 
transcriptional events and Smad-independent effects on cell 
junction complexes. Smad-mediated expression of HMGA2 
(high-mobility group A2) induces expression of Snail, Slug, 
and Twist (Thuault et al., 2006). Independent of Smad activity, 
TβRII-mediated phosphorylation of Par6 promotes the dissolu-
tion of cell junction complexes (Ozdamar et al., 2005). In mouse 
tumors and cell lines, TGFβ-induced EMT is Smad dependent 
and enhanced by Ras signaling (Derynck and Akhurst, 2007). 
TGFβ can also enhance cell motility by cooperating with HER2 
signals, as observed in breast cancer cells overexpressing 
HER2 (Seton-Rogers et al., 2004).
Myofibroblast Generation
The mobilization of myofibroblasts is another significant com-
ponent of the proinvasive action of TGFβ. TGFβ stimulates the 
generation of myofibroblasts from mesenchymal precursors 
(De Wever and Mareel, 2003) (Figure 6). Myofibroblasts have 
features of fibroblasts and smooth muscle cells and are highly 
motile. Their presence in tumor stroma, partly as what are 
called “cancer-associated fibroblasts,” facilitates tumor devel-
opment (Allinen et al., 2004; De Wever and Mareel, 2003). In 
culture, myofibroblasts guide the invasion of colon cancer cells 
into a collagen matrix, a process that requires the continuous 
presence of TGFβ. Myofibroblasts produce matrix metallo-
proteases, cytokines (e.g., IL-8, VEGF), and chemokines (e.g., 
CXCL12) to promote cancer cell proliferation, tumor invasion, 
and neoangiogenesis.
Production of Autocrine Mitogens
TGFβ can promote tumor cell proliferation by stimulating the 
production of autocrine mitogenic factors. The loss of the TGFβ 
tumor suppressor arm in glioma, owing to PI3K hyperactiva-
tion, loss of p15INK4b, or mutational inactivation of RB, allows 
glioma cells to profit from TGFβ-induced mitogen production. 
Glioma cell cultures proliferate in response to TGFβ through the 
induction of platelet-derived growth factor B (PDGF-B) (Jen-
nings and Pietenpol, 1998). The competence of glioma cells to 
express PDGF-B in response to TGFβ depends on the methy-
lation state of the PDGF-B gene (Bruna et al., 2007). Hypo-
methylation of PDGF-B enables TGFβ- and Smad-dependent 
transcription induction and is associated with poor prognosis 
in cancer patients. Epigenetic regulation of the PDGF-B gene 
therefore dictates the ability of TGFβ to stimulate glioma cell 
proliferation.
Evasion of Immunity
When the immunosuppressive effects of TGFβ outweigh the 
tumor-suppressive benefits of its anti-inflammatory action, a net 
protumorigenic advantage may result (Figure 7D). T cell-specific 
expression of a dominant-negative form of TGFBRII prevented 
the growth of inoculated melanoma or thymoma in mice (Gorelik 
and Flavell, 2000). CD8+ T cells were identified as a critical tar-
get of TGFβ in this model. TGFβ acting through the Smad path-
way in CD8+ CTLs represses the production of cytolytic factors 
including the pore-forming protein perforin, the caspase-acti-
vating secreted factors granzyme A and B, and the proapoptotic 
cytokines Fas-ligand and IFN-γ (Thomas and Massagué, 2005). 
In human glioma patients, TGFβ decreases the expression of the 
activating immunoreceptor NKG2D in CD8+ T cells and NK cells 
and represses the expression of the NKG2D ligand MICA (Fri-
ese et al., 2004). Knockdown of TGFβ synthesis in a glioma cell 
line prevented NKG2D downregulation and enhanced glioma 
cell killing by CTL and NK cells. Thus, glioma development may 
thrive on both the immunosuppressive action of TGFβ and the 
TGFβ-induced production of PDGF.
TGFβ in Distal Metastasis
In addition to the role of TGFβ in local invasion, growing evi-
dence implicates TGFβ in the promotion of distal metastasis. 
Metastasis proceeds through a series of steps whereby cancer 
cells enter the circulatory system, disseminate to distal capil-
lary beds, enter a parenchyma by extravasation, adapt to the 
new host microenvironment, and eventually grow into lethal 
tumor colonies in those distal organs (Fidler, 2003; Gupta and 
Massagué, 2006). Metastasis follows characteristic organ dis-
tribution patterns that reflect distinct colonization aptitudes of 
cancer cells from different origins, different tumor-efferent cir-
culation patterns, and distinct compatibilities between dissem-
inated cells and the organ that they encounter. Beyond the pro-liferative, survival, and invasive functions of a malignant state, 
metastasis requires extravasation and colonization functions 
that come into play once malignant cells disseminate. Such 
functions may be acquired in the primary tumor but become 
selected mainly during seeding and colonization of largely hos-
tile tissue microenvironments. Studies in model systems have 
described a broad range of potential and sometimes contra-
dictory TGFβ effects on metastasis. Those with demonstrated 
clinical relevance are highlighted here.
TGFβ and Metastatic Relapse
Clinical correlations between pre- or postoperative plasma lev-
els of TGFβ and metastatic disease have been reported in many 
studies on colorectal, prostate, bladder, breast, pancreatic, or 
renal cancers and on myeloma and lymphoma. A high level of 
TGFβ1 immunostaining in infiltrating breast carcinoma has long 
been associated with metastasis (Dalal et al., 1993). Indeed, in 
ER− breast tumors, low expression of TGFBRII is associated 
with a favorable outcome (Buck et al., 2004). Furthermore, the 
treatment of mammary tumor-bearing mice with radiation or 
chemotherapy caused an increase in circulating TGFβ1 levels 
and lung metastasis, which could be prevented by administra-
tion of a TGFβ blocker (Biswas et al., 2007). These observa-
tions point at a potential link between TGFβ production and 
metastatic disease. However, TGFβ signaling has shown dis-
parate effects on metastasis in mouse models. The expression 
of activated a TGFBRI transgene in mouse mammary tumors 
driven by ErbB2/HER2 oncogenes enhanced metastasis of 
these tumors to the lungs (Muraoka et al., 2003; Siegel et al., 
2003). However, a targeted deletion of TGFBRII in PyMT-driven 
tumors did the same (Forrester et al., 2005). Similarly, a domi-
nant-negative form of TGFBRII inhibited metastasis of human 
prostate cancer cells when implanted in the mouse prostate 
(Zhang et al., 2005) but promoted metastasis as a transgene in 
mouse prostate tumors driven by SV40 large T antigen (Tu et 
al., 2003). How can this contextual role of TGFβ be explained at 
the molecular level and ascertained in human cancer?
One possible approach is based on classifying human 
tumors according to their TGFβ response status and search-
ing for associations with clinical outcome. To this end, a TGFβ 
gene response signature was defined using human epithelial 
cell lines and turned into a bioinformatics classifier tool (Padua 
et al., 2008). In different clinical cohorts, approximately 40% 
of human breast tumors show a TGFβ gene response signa-
ture, and this status coincided with a high expression of TGFβ1, 
TGFβ2, LTBP1, SMAD3, and SMAD4. Interestingly, a TGFβ gene 
response signature status was associated with lung relapse 
but not bone relapse. It was also associated with ER− but not 
ER+ primary tumors. The contextual role of TGFβ in this case is 
a function of the tumor subtype (ER− versus ER+ breast tumors) 
and the site of relapse (lungs versus bones). Of course, this 
argues against a generic, noncontextual effect of TGFβ (e.g., 
increased cancer cell motility or invasiveness) playing a major 
role in breast cancer metastasis.
Priming Tumor Cells for Distal Metastasis
Investigation of the biologically selective, context-dependent 
mechanism implied by these observations led to the finding 
that TGFβ in the breast tumor microenvironment primes cancer 
cells for subsequent pulmonary metastasis (Padua et al., 2008). Cell 134, July 25, 2008 ©2008 Elsevier Inc. 225
Blocking TGFβ signaling with a dominant-negative form of TGF-
BRI or SMAD4 knockdown in an ER− human breast cancer cell 
line decreased the ability of these cells to generate lung metas-
tases when implanted as mammary tumors in mice. Central to 
this process was the induction of angiopoietin-like 4 (ANGPTL4) 
by TGFβ via the Smad signaling pathway. TGFβ in the primary 
tumor induced the expression of Angptl4 in departing cancer 
cells, empowering these cells to disrupt lung capillary walls 
and seed pulmonary metastases (Figure 8). Tumor cell-derived 
Angptl4 disrupted vascular endothelial cell-cell junctions, 
increased the permeability of lung capillaries, and facilitated the 
transendothelial passage of tumor cells. This function of Angptl4 
could explain why it does not provide an advantage for seed-
ing bone metastasis: The capillary walls in the bone marrow are 
already fenestrated to facilitate the passage of hematopoietic 
cells. TGFβ-induced Angptl4 does not act alone, but functions in 
the context of other prometastatic genes that constitute a lung 
metastasis signature (LMS) in ER− tumors (Minn et al., 2005). 
ER− breast tumors that are positive for both the TGFβ gene 
response signature and LMS are associated with the highest 
risk of relapse through lung metastases. Thus, the TGFβ gene 
response signature provides not only a tool to discern the con-
textual role of TGFβ in different tumor subtypes but also a poten-
tial way to select patients for TGFβ blocking therapy.
Figure 8. Roles of TGFβ in Breast Cancer Metastasis
Based on recent reports, TGFβ derived from infiltrating mesenchymal or myel-
oid precursor cells (green) or from the cancer cells themselves (brown) in ER− 
breast tumors induces the expression of genes including Angiopoietin-like 4 
(ANGPTL4; primary breast tumor inset). Cancer cells entering the circulation 
with elevated Angptl4 production have an advantage in seeding lung metas-
tasis because of this cytokine’s ability to disrupt vascular endothelial junctions 
when the cells lodge in lung capillaries (lung metastasis inset). After entering 
the pulmonary parenchyma, ER− breast cancer cells may respond to local 
TGFβ with induction of Inhibitor of Differentiation/DNA binding 1 (ID1), which 
acts in this context as a tumor-reinitiating gene. The entry of circulating tu-
mor cells into the bone marrow does not benefit from Angptl4 because these 
capillaries are naturally fenestrated to allow the constant passage of cells 
(bone metastasis inset). However, TGFβ released by osteoclasts (blue) from 
rich stores in the bone matrix acts on the growing cancer cells to stimulated 
the production of parathyroid hormone-related protein (PTHrP) and interleu-
kin-11. These factors act on osteoblasts to release RANK ligand (RANKL) 
and other mediators of osteoclast moblization, perpetuating the osteolytic 
metastasis cycle.226 Cell 134, July 25, 2008 ©2008 Elsevier Inc.TGFβ and Metastatic Colonization
Once distant metastases take hold, local production of 
TGFβ can profoundly affect the growth of these lesions. In 
mouse models, the osteoclastic activity triggered by cancer 
cells in the bone marrow leads to the release of TGFβ from 
rich bone matrix stores. TGFβ may then stimulate the can-
cer cells to release osteolytic cytokines, thus perpetuating a 
prometastatic cycle (Kingsley et al., 2007) (Figure 8). Meta-
static breast cancer cells in the bone microenvironment are 
engaged in Smad-dependent transcription, as shown by a 
noninvasive imaging reporter in mice (Kang et al., 2005). 
Indeed, blocking TGFβ signaling by overexpressing the inhib-
itor Smad7 or a dominant-negative form of the TGFβ recep-
tor deters the formation of osteolytic metastases by human 
breast cancer (Yin et al., 1999), melanoma (Javelaud et al., 
2007), and renal carcinoma cell line xenografts (Kominsky 
et al., 2007). One of the mediators of TGFβ osteolytic action 
is parathyroid hormone-related protein (PTHrP) (Kingsley et 
al., 2007). TGFβ stimulates PTHrP secretion without appear-
ing to increase PTHrP mRNA levels. PTHrP stimulates the 
production of RANK ligand (RANKL) in osteoblasts, which 
in turn promotes the differentiation of osteoclast precursors 
and bone resorption. Administration of anti-PTHrP neutral-
izing antibodies inhibits TGFβ-dependent osteolytic bone 
metastasis in mice (Kakonen et al., 2002).
Additional mediators include a set of genes that modulate 
bone metastasis in mice by human ER− breast cancer cells 
(Kang et al., 2003a). Among these genes, interleukin-11 (IL-11) 
and connective tissue growth factor (CTGF) are TGFβ tar-
get genes. CTGF is an extracellular mediator of invasion and 
angiogenesis, whereas IL-11 stimulates the production of the 
osteoclastogenic factors RANKL and GM-CSF in osteoblasts. 
Induction of IL-11 and CTGF expression by TGFβ is mediated 
by the Smad pathway (Kang et al., 2005) and has been con-
firmed in malignant cells isolated from patients with metastatic 
breast cancer (Gomis et al., 2006b).
The role of TGFβ in metastatic colony expansion may not 
be limited to bone metastasis. A majority of metastases to 
lung, liver, and brain in breast cancer patients stain positive for 
phospho-Smad2, suggesting a widespread activation of this 
pathway in metastasis by locally released TGFβ. In breast can-
cer cells that have entered the pulmonary parenchyma, TGFβ 
may facilitate tumor reinitiation through an aberrant induction 
of ID1 expression (Padua et al., 2008).
Therapeutically Targeting TGFβ: Challenges and 
Opportunities
With growing clinical evidence that TGFβ acts as a tumor-
derived immunosuppressor, an inducer of tumor mitogens, a 
promoter of carcinoma invasion, and a trigger of prometa-
static cytokine secretion, there is growing interest in TGFβ 
as a therapeutic target. In spite of the sobering concerns 
that apply to targeting a pleiotropic cytokine pathway, anti-
TGFβ compounds have been developed that show efficacy 
in preclinical studies, and clinical trials with several of these 
compounds are underway (for more detailed commentaries, 
see Arteaga, 2006; Bierie and Moses, 2006; Wrzesinski et 
al., 2007). Inhibitors of the TGFβ pathway developed to date 
Cell 134, July 25, 2008 ©2008 Elsevier Inc. 227encompass several classes. These include inhibitors of TGFβ 
production (antisense oligonucleotides) that can be engi-
neered into immune cells or delivered directly into tumors. 
They also include inhibitors of ligand-receptor interactions 
such as anti-TGFβ antibodies, anti-receptor antibodies, 
TGFβ-trapping receptor ectodomain proteins, and small-mol-
ecule inhibitors that target TGFβ receptor kinases. Members 
of each of these inhibitor classes have entered clinical tri-
als for efficacy not only against cancers (glioma, melanoma, 
breast cancer) but also against fibrosis, scarring, and other 
conditions that result from excessive TGFβ activity.
Therapeutic targeting of the TGFβ pathway in tumors such 
as glioma, melanoma, and renal cell carcinoma is based on 
the rationale that TGFβ exerts strong immunosuppressive 
effects in these tumors. Thus, blocking TGFβ function might 
empower the immune system against the tumor. Blocking 
TGFβ action may also have additional tumor-specific ben-
efits. For example, TGFβ inhibition in gliomas may curtail 
the production of autocrine survival factors, such as PDGF. 
Blocking TGFβ in ER− breast cancer, on the other hand, 
might prevent primary or metastatic tumors from seeding 
and reseeding metastasis. Finally, in osteolytic bone metas-
tasis, blocking TGFβ might interrupt the cycle of TGFβ-
induced osteoclastogenic factors and halt tumor growth. 
Although these examples show the great potential of the 
pathway as a therapeutic target, there are potential nega-
tive consequences, as well. Inhibition of TGFβ might lead to 
chronic inflammatory and autoimmune reactions, although 
this problem has not yet materialized in the preclinical or 
clinical trials of systemic TGFβ blockers. Inhibition of TGFβ 
receptor function might also lead to runaway compensatory 
mechanisms by other activators of the Smad pathway, simi-
lar to what occurs in individuals with inactivating mutations 
in TGFBRI or TGFBRII (Loeys et al., 2006). Lastly, inhibition 
of TGFβ signaling might enhance the progression of prema-
lignant lesions. Of course, this would be a lesser concern in 
cancer patients whose malignancies are thriving on TGFβ. 
Reassuringly however, systemic administration of TGFβ 
blockers has not been reported to increase spontaneous 
tumor development in animal models.
Progress in delineating the protumorigenic effects and 
mechanisms of TGFβ in specific tumor types and in differ-
ent stages of cancer progression is essential for determining 
when and how anti-TGFβ targeted therapy might be feasible. 
The recent development of TGFβ gene expression prognos-
tic tools and TGFβ response biomarkers may provide the 
means to select patients for anti-TGFβ intervention in addi-
tion to a way to assess effective pharmacological targeting 
of this pathway. Analysis of the TGFβ signaling pathway in 
experimental models and human samples has brought much 
needed clarity to the role and relevance of TGFβ in human 
cancer, bringing this once obscure problem to the cusp of 
clinical tractability.
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